QBIO Stock Analysis
QB
Uncovered
Q BioMed Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Q BioMed, Inc. operates as a biomedical acceleration and development company. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2014-11-17. The firm focuses on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed acquires assets across healthcare related products, companies and sectors. The company has portfolio of five therapeutic products, including Strontium-89 and MetastronTM for metastatic bone cancer pain and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder; Uttroside-B for liver cancer, and MAN 01 for glaucoma. Its MAN platform has therapeutics in development in various indications, including vascular and infectious diseases. The company holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of bone cancer. The infectious diseases that it can treat includes influenza, COVID-19, Ebola and others. The firm's subsidiaries include Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG.